Gut microbiome signatures linked to HIV-1 reservoir size and viremia control

Simple item page
dc.contributor.authorBorgognone, Alessandra
dc.contributor.authorNoguera-Julian, Marc
dc.contributor.authorOriol, Bruna
dc.contributor.authorNoël-Romas, Laura
dc.contributor.authorRuiz-Riol, Marta
dc.contributor.authorGuillén, Yolanda
dc.contributor.authorParera, Mariona
dc.contributor.authorCasadellà, Maria
dc.contributor.authorDuran, Clara
dc.contributor.authorPuertas, Maria C.
dc.contributor.authorCatalà-Moll, Francesc
dc.contributor.authorDe Leon, Marlon
dc.contributor.authorKnodel, Samantha
dc.contributor.authorBirse, Kenzie
dc.contributor.authorManzardo, Christian
dc.contributor.authorMiró, José M.
dc.contributor.authorClotet, Bonaventura
dc.contributor.authorMartinez-Picado, Javier
dc.contributor.authorMoltó, José
dc.contributor.authorMothe, Beatriz
dc.contributor.authorBurgener, Adam
dc.contributor.authorBrander, Christian
dc.contributor.authorParedes, Roger
dc.date.accessioned2022-05-01T03:21:45Z
dc.date.issued2022-04-11
dc.date.updated2022-05-01T03:21:45Z
dc.description.abstractAbstract Background The potential role of the gut microbiome as a predictor of immune-mediated HIV-1 control in the absence of antiretroviral therapy (ART) is still unknown. In the BCN02 clinical trial, which combined the MVA.HIVconsv immunogen with the latency-reversing agent romidepsin in early-ART treated HIV-1 infected individuals, 23% (3/13) of participants showed sustained low-levels of plasma viremia during 32 weeks of a monitored ART pause (MAP). Here, we present a multi-omics analysis to identify compositional and functional gut microbiome patterns associated with HIV-1 control in the BCN02 trial. Results Viremic controllers during the MAP (controllers) exhibited higher Bacteroidales/Clostridiales ratio and lower microbial gene richness before vaccination and throughout the study intervention when compared to non-controllers. Longitudinal assessment indicated that the gut microbiome of controllers was enriched in pro-inflammatory bacteria and depleted in butyrate-producing bacteria and methanogenic archaea. Functional profiling also showed that metabolic pathways related to fatty acid and lipid biosynthesis were significantly increased in controllers. Fecal metaproteome analyses confirmed that baseline functional differences were mainly driven by Clostridiales. Participants with high baseline Bacteroidales/Clostridiales ratio had increased pre-existing immune activation-related transcripts. The Bacteroidales/Clostridiales ratio as well as host immune-activation signatures inversely correlated with HIV-1 reservoir size. Conclusions The present proof-of-concept study suggests the Bacteroidales/Clostridiales ratio as a novel gut microbiome signature associated with HIV-1 reservoir size and immune-mediated viral control after ART interruption. Video abstract
dc.identifier.citationMicrobiome. 2022 Apr 11;10(1):59
dc.identifier.urihttps://doi.org/10.1186/s40168-022-01247-6
dc.identifier.urihttp://hdl.handle.net/1993/36455
dc.language.rfc3066en
dc.rightsopen accessen_US
dc.rights.holderThe Author(s)
dc.titleGut microbiome signatures linked to HIV-1 reservoir size and viremia control
dc.typeJournal Article
local.author.affiliationRady Faculty of Health Sciencesen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
40168_2022_Article_1247.pdf
Size:
4.35 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.24 KB
Format:
Item-specific license agreed to upon submission
Description:
Download
Collections
University of Manitoba Scholarship
Rady Faculty of Health Sciences Scholarly Works